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Abstract
Panax notoginseng saponin (PNS) is the main active gradient of Chinese traditional medicine Panax notoginseng.
Although its prominent therapeutic efficacy has been demonstrated by various researchers, the broader application
is restricted by the low bioavailability of PNS. This article aims to discuss PNS’s plasma pharmacokinetics after oral
administration of bio-adhesive tablet of PNS to beagle dogs and improve its bioavailability in comparison with
normal tablet. The bio-adhesive tablet was prepared according to our previous patent, using chitosan as main
excipient. A simple and sensitive LC-MS/MS combined with solid-phase extraction (SPE) method for the analysis of
PNS in dog’s plasma was developed in our previous study, and was validated to apply in the pharmacokinetics
study in this work. Three ingredients: Notoginsenoside R1 (R1), Ginsenoside Rg1 (Rg1) and Ginsenoside Rb1 (Rb1)
(Figure 1), were chosen as indicators of PNS to analyze it in vivo. Statistically significant increase (P < 0.05) in
pharmacokinetic parameters of PNS including AUC and Tmax for R1, Rg1 and Rb1, Cmax for R1 and Rb1, MRT for
Rg1 were obtained after oral administration of bio-adhesive tablet of PNS comparing with its normal tablet. The
formulation modification of using chitosan to prepare bio-adhesive tablet for oral administration is effective in
improving the bioavailability of PNS, thereby enhancing its potential therapeutic effect and broadening its clinical
application.
1. Introduction
Panax notoginseng (Burk.) F.H. Chen is an important
traditional Chinese medicine mainly produced in Yun-
nan, Guangxi and Szechwan in China.Panax notoginseng
saponin (PNS), the extract of Panax notoginseng,h a s
been generally studied. PNS possesses many pharmaco-
logical active effects, including resistance against cere-
bral infarction and ischemia by inhibiting apoptosis and
expression of caspase-1 and caspase-3 [1,2]; antioxidant
property by its strong ferrous ion chelating activity
scavenging activities against hydrogen peroxide, hydro-
xyl radicals, superoxide anion and DPPH free radicals
[3]; therapeutic effect on atherosclerosis by lowering
serum lipid level and regulating expression of vascular
cell differentiation antigen 40 and matrix metalloprotei-
nase 9 [4]. In recent years, increasing attention has been
paid to other activities of PNS: neuroprotective activity
based on its potent protective effect against blood-brain
barrier damage) [5]; anti-hyperglycemic and anti-obese
effects by lowering fasting blood glucose levels and
improving glucose tolerance [6]; anti-platelet and anti-
coagulant effects [7]; anti-inflammatory in vitro proper-
ties via blocking NF-B signaling pathway in macro-
phages [8]; anti-depressive activity that may be mediated
by modulation of brain monoamine neurotransmitters
and intracellular Ca2+ concentration (Xiang et al.: The
antidepressant effects and mechanism of action of total
saponins from the caudexes and leaves of Panax noto-
ginseng in animal models of depression, submitted).
Currently, there are some commercial formulations of
PNS in China, including XUESAITONG tablet, injection
and lyophilized powder injection. However, the oral bioa-
vailability of PNS is not satisfying, and it is documentarily
reported that some adverse reactions such as epistasis,
allergy and even anaphylactic shock might be caused by
using PNS injection [9]. In order to avoid such serious
adverse effects as well as to improve the oral bioavailabil-
ity of PNS, developing more appropriate formulation is
urgently needed. In our lab’s previous studies, we applied
a widely used bio-adhesive excipient, carbopol, to make
bio-adhesive tablet [10]. However, chitosan is a more
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median lethal dose (LD50) for mice after oral administra-
tion of chitosan is 16 g/kg. Thus the toxicity of chitosan
is considerably lower than carbopol, the LD50 of which is
2.5 g/kg [11]. Based on the consideration of choosing an
excipient with lower toxicity, in this study we used chito-
san to prepare bio-adhesive tablet.
Researchers have done some pharmacokinetics studies
of PNS [12,13], most of these studies chose Ginsenoside
Rg1 or Ginsenoside Rb1 as indicator of PNS for analyz-
ing. Although reported detection method simultaneously
analyzed Notoginsenoside R1, Ginsenoside Rg1, Rd, Re
and Rb1 in rat plasma by HPLC/ESI/MS [14], their sam-
ple preparation method using liquid-liquid extraction is
different from our solid-phase extraction (SPE) method.
In our study, we adopted a liquid chromatography-tan-
dem mass spectrometry (LC/MS/MS) combined with
SPE method established in our previous study to simul-
taneously detect Notoginsenoside R1, Ginsenoside Rg1
and Rb1 to reflect the veritable pharmacokingetics prop-
erties of PNS in plasma sample of beagle dogs [15]. The
chemical structures of the three components are shown
in Figure 1. It is expected that this research would be
effective for improving bioavailability of PNS and their
clinical therapeutic efficacy, and can serve as a signifi-
cant foundation for further pharmacological studies of
PNS.
2. Experimental
2.1. Instruments
Blood samples were pretreated with extract-clean C18
(solid-phase extraction) cartridge columns (1 mL,
packed with 100 mg of 40 μm octadecyl silica) (Alltech
Company, Deerfield, USA). The assay was performed on
an Agilent 1100 series HPLC system (Agilent Technolo-
gies, Waldbronn, Germany) consisting of a quaternary
pump, a triple quadrupole mass spectrometry detector,
an autosampler, a vacuum Degasser and a column oven.
The mass spectrometer (ABI, USA) equipped with a tur-
boIonspray source was used for the analysis. The mobile
phase with the flow rate of 0.2 ml/min consisting of 10
mM ammonium acetate solution, 0.1% n-butyl-amine,
10% methanol in water (A) and methanol (B). The sys-
tem was run by a gradient program of 50% B to 90% B
in five minutes and 90% B to 50% B in three minutes.
Single-punch tablet press (TDP, Tianxiang pharmaceuti-
cal machinery factory, Shanghai)
2.2. Materials
PNS extract was purchased from the Institute of Medic-
inal Plant Development, Yunnan Branch (Yunnan Pro-
vince, China). PNS extract contained 37% of Rg1, 36%
of Rb1, and 10% of R1, respectively, according to HPLC
analysis. Standards of R1, Rg1 and Rb1 were purchased
from the National Institute of the Control of Pharma-
ceutical and Biological Products (Beijing, China). In
addition, Glipizide (internal standard) was generously
provided by Professor Jifen Guo at the Academy of Mili-
tary Medical Sciences (Beijing, China). Chitosan was
purchased from Jinqiao Biochemistry Company (Zhe-
jiang, China). Acetonitrile and methanol (HPLC grade)
were purchased from Fisher Scientific (New Jersey,
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Figure 1 Chemical structures of Ginsenoside Rb1 (A),
Ginsenoside Rg1 (B) and Notoginsenoside R1 (C).
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Six male beagle dogs, weighing at 10-12 kg, from Tongli
Laboratory Animals Center (Beijing, China) were
adopted in the animal experiments. The Experiments
were carried out in accordance with international
accepted guidelines on laboratory animal use, the Guide
for the care and use of laboratory animals (Institute of
Laboratory Animal, Washington, D.C. National Acad-
emy Press 1996), and the protocols were approved by
the Beijing Animal Care Committee (Beijing, China).
2.4. Preparation of blood samples
Solid phase extraction (SPE) cartridges were precondi-
tioned by passing through 2 ml of methanol followed by
2 ml of water before loading. 0.5 ml plasma sample was
applied to solid phase extraction cartridge (1 ml, packed
w i t h1 0 0m go f4 0μm octadecyl silica) and drawn
through by gravity. The cartridge was washed chronolo-
gically with 2 ml of water, 2 ml of 20% (v/v) aqueous
methanol solution, and 2 ml of methanol. The final
methanol eluate was collected and 10 μL of internal
standard was added to it. The eluate was thereafter eva-
porated at 60°C to dryness under a stream of nitrogen.
The residue was dissolved in 100 μL of 50% (v/v) aqu-
eous methanol solution. A 20 μL sample was injected
into the HPLC system for analysis.
2.5. Preparation of normal and bio-adhesive tablet of PNS
We prepared normal tablet and bio-adhesive tablet
according to our previous patent (Patent number:
ZL200510073274.4). The ratio between PNS and other
excipients in our two kinds of tablets was PNS: chitosan:
other excipients = 60:40:100. Based on the standard of
commercial XUESAITONG tablet, the dosage of PNS in
our both bio-adhesive and normal tablet was 50 mg. We
homogeneously mixed PNS with other excipients except
chitosan after sifting, and used ethanol to wet-granulate
particles. The particles passed through 20-mesh sieve
were dried at 60°C. Then they were mixed with chitosan
and magnesium stearate and were compressed into
tablets by using a single-punch tablet press. Normal
tablet was prepared by the similar ratio and method,
without adding chitosan.
2.6. Administration of PNS and sample collection
According to our double cycle and crossover experimen-
tal design, normal and bio-adhesive tablets were admi-
nistered orally at a dose of 90 mg/kg to six beagle dogs.
All dogs were deprived of food but given free access to
water for 12h before the experiments. Blood samples (3
ml each time) were collected via fore leg vein of dogs
according to the specific time intervals of at 0, 0.5, 1, 2,
3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72h after administration.
The plasma was separated after centrifugation for
10 mins at 3000 r·min
-1 a n ds t o r e da t- 2 0 ° Cf o rt h e
further analysis.
2.7. In vivo pharmacokinetic study
All the data was processed by non-compartmental ana-
lysis using the Phoenix WinNonlin 6.1 (Pharsight, USA),
and then was analyzed by SPSS software to judge its
significance.
3. Results and Discussion
3.1. Validation of LC-MS/MS methods
The specificity was evaluated by comparing chromato-
grams of blank plasma (from six different dogs), blank
plasma spiked with R1, Rg1, Rb1, internal standard, and
plasma samples after oral administration of by bio-adhe-
sive tablet of PNS. As they were shown in Figure 2, 3,
and 4, these chromatographic conditions revealed that
there was no significant interfering endogenous peak
observed within the period where R1, Rg1, Rb1 and inter-
nal standard were detected. Linearity of the calibration
curves was found over the range of 2.8-140 ng for R1,
3.8-190 ng for Rg1 and 18-900 ng for Rb1. The equation
of calibration curve for R1 was y = 0.0024x + 0.0068 (r
2 =
0.9967), for Rg1 was y = 0.001x + 0.0015 (r
2 = 0.9991);
for Rb1 was y = 0.001x + 0.0197 (r
2 = 0.9982). The accu-
racy and precision were evaluated by quality control sam-
ples at low (2.8 ng/ml for R1, 3.8 ng/ml for Rg1 and
18 ng/ml for Rb1), medium (14 ng/ml for R1, 19 ng/ml
for Rg1 and 180 ng/ml for Rb1), and high (140 ng/ml for
R1, 190 ng/ml for Rg1 and 900 ng/ml for Rb1) concentra-
tions which were prepared in the same way as calibration
standards. The intra-batch accuracy and precision of the
assay were assessed by quality control samples analysis at
three concentrations in six replicates and the inter-batch
was detected by analyzing them in three batches. The
results met our requirement for detecting, and the
detailed data have been published in our previous
research article [15]. The relative recovery for R1 was
96.02% at 2.8 ng/ml, 104.02% at 14 ng/ml and 102.32% at
140 ng/ml; for Rg1 was 99.92% at 3.9 ng/ml, 102.40% at
19 ng/ml and 98.96% at 190 ng/ml; for Rb1 was102.67%
at 18 ng/ml, 101.13% at 180 ng/ml and 105.00% at 900
ng/ml, the standard deviations were lower than 10.2%.
The validated method was proved to be sensitive, reliable
and the data demonstrated that this method was success-
fully applied to study the pharmacokinetics of PNS in
beagle dogs after oral administration of PNS tablets.
3.2. Pharmacokinetic applications and plasma drug
concentration-time curves of six beagle dogs
The highly developed digestive system of beagle dog is
more similar to human and is more appropriate for
pharmacokinetics study of medicine, especially for medi-
cine passing through gastrointestinal tract [16]. In this
Feng et al. International Archives of Medicine 2011, 4:18
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PNS in dogs, which is useful top r e f i g u r ei t sp o t e n t i a l
efficacy when it is administered to human being. The
concentration-time curves of three components of six
dogs were shown in Figure 5. All three concentration-
time curves of bio-adhesive tablet of PNS shared a simi-
lar multiple-peak phenomenon. Our result was inconsis-
tent with Xu’s report [12], in which the rats’
concentration-time curves of Rg1 and Rb1 were single-
peak. In Xu’s report, they failed to detect Rg1 in rats’
serum after 24h, while we detected R1, Rg1 and Rb1 till
72h. The reason of this inconsistence might be the dif-
ferences of administrating doses, analytical methods and
formulation modifications between the previous and
present studies. In our study, 90 mg/kg PNS tablet was
orally administered to beagle dogs while the dose of
PNS in documental reports was 600 mg/kg. Owing to
our improved analytical method, the PNS blood concen-
tration could be detected at nanogram level compared
to the microgram level of Xu’s report. By virtue of the
improvement of our more sensitive detection method,
we could reveal more veritable pharmacokinetics prop-
erties of PNS after oral administration.
Specifically, there were several potential factors contrib-
uted to multiple-peak phenomenon showed in all three
ingredients’ results: Because of the gastric emptying effect,
drug got to small intestine where it was primarily absorbed
nonsynchronously and hence entered the blood at differ-
ent time; PNS was absorbed at different positions in gas-
trointestinal tract and each position had different
absorption rate; Enterohepatic circulation: the two or
more peaks occurred in three concentration-time curves
might be caused by the hydrolytic effects of some bacterial
enzymes or the influence that bile released intermittently
during the process of re-absorption of PNS; Moreover,
according to previous pharmacokinetics research, R1, Rg1
and Rb1 had a great distribution in several organs, espe-
cially in kidney, heart and liver [17-19]. Thus their redistri-
bution effect might also be another possible cause for the
multiple-peak phenomenon occurred in our study.
When we compared the pharmacokinetics property of
Rb1 with R1 and Rg1, we found that there were more
                 
 
Figure 2 Chromatograms under LC/MS/MS conditions for analyzing beagle dog plasma spiked with Notoginsenoside R1 (A),
Ginsenoside Rg1 (B), Ginsenoside Rb1 (C) and internal standard glipizide (D). MS/MS transitions monitored in the positive ion mode were
from m/z 1007 to m/z 423 for R1 (MW 932), from m/z 875 to m/z 423 for Rg1 (MW 800), from m/z 1183 to m/z 487 for Rb1 (MW 1108), and
from m/z 494 to m/z 369.1 for internal standard. Intensity cps: ion intensity is in counts per second. The retention time is 1.67 min for R1, 1.56
min for Rg1, 3.81 min for Rb1 and 1.86 min for I.S.
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and Rg1. Besides, we detected high concentration of
Rb1 in plasma till 72h, while the concentrations of the
other two ingredients in plasma are quite low after 36h.
It can be inferred that several possible reasons besides
those we had discussed above may combine together to
account for the different pharmacokinetics property of
Rb1: In Han’s research, the protein-binding rate in
plasma for Rb1 (80.11~89.69%) was considerably higher
than Rg1(6.56~12.74%), the protein-binding effect could
prolong the existence of Rb1 in plasma, and the process
that Rb1 dissociated from protein in plasma to release
uncombined ingredient maybe related with more peaks
in Rb1’s concentration-time curve. Moreover, Rb1 might
be absorbed in colon. Although previous study reported
that Rb1 was degraded evidently in large intestine [20],
chitosan was able to improve the stability of PNS, espe-
cially Rb1, due to its ability to improve the distribution
of intestinal microorganisms, to inhibit the biological
synthesis at the surface of bacteria’s cell membrane and
damage the transmission of energy crossed through it.
Based on such mechanisms, chitosan reduced the degra-
dation of Rb1 and enabled it to be absorbed in colon.
Additionally, other ingredients in PNS might affect the
absorption of Rb1. Considering of the experimental con-
dition and animal-protectionism, we only used 6 beagle
dogs in this study. So it was unreasonable to deny the
possibility of individual difference between dogs as well
as its influence on the result of our pharmacokinetics
study. Using more beagle dogs might enable the result
more persuasive, but it was not covered by this current
study. The pharmacokinetics property of Rb1 was very
complex and should be subjected to further study.
3.3. The relative bioavailability and other
pharmacokinetics parameters
The parameters of AUC for R1, Rg1 and Rb1 between
normal tablet and bio-adhesive tablet were increased
remarkably (P < 0.05), and the relative bioavailability
after oral administration of bio-adhesive tablets is
204.53% for R1, 152.73% for Rg1 and 150.50% for Rb1.
This result (Table 1) indicates that bio-adhesive formu-
lation considerably improved the oral bioavailability of
PNS. The parameter of Tmax for R1, Rg1 and Rb1 was
significantly increased (P < 0.05). The parameter of Cmax
for R1 and Rb1 between normal tablet and bio-adhesive
tablet was increased remarkably (P < 0.05), which
reveals that there was a process of accelerating release
Figure 3 Chromatograms under LC/MS/MS conditions for analyzing beagle dog plasma sample 2 h after oral administration of bio-
adhesive tablet of PNS at dose of 90 mg/Kg. Notoginsenoside R1 (A), Ginsenoside Rg1 (B), Ginsenoside Rb1 (C) and internal standard (D)
were detected respectively. The retention time is 1.75 min for R1, 1.63 min for Rg1, 4.00 min for Rb1 and 1.93 min for I.S.
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cal difference of Cmax for Rg1 between two kinds of
tablet, its MRT was significantly prolonged from 6.40h
to 11.54h (P < 0.05), which indicated that the improve-
ment of AUC of Rg1 was attributable to a prolonged
assimilation and slow release. It can be inferred that the
increase of MRT for Rg1 was probably the result of
prolonging drug’s residence time in gastrointestinal tract
based on chitosan’s specific properties of polymeric
cationic, gelling and adhesivity. Chitosan’s expansibility
in vivo might retard the release of Rg1, and Rg1’sh i g h
protein-binding rate in liver maybe another possible
reason.
The improvement of AUC for R1 and Rb1 were
more likely a consequence of increasing permeation of
drug through intercellular space by reducing the trans-
membrane electric resistance of epidermal cell. The
permeation might be further increased by the electro-
static interaction between positively charged chitosan
and negative charged cell membrane. The different
spatial structures of three components might also
account for the different mechanisms upon which they
relied to enhance AUC.
The formulation modification of bio-adhesive tablet
using chitosan might be closely related with the changes
of pharmacokinetics properties of PNS. Chitosan was
applied in our study based on its unique advantages: 1.
Low oral toxicity and good biocompatibility that guaran-
tee sufficient safety for using. Chitosan was degraded
into low molecular oligosaccharide by lysozgme or
NAG, such product cannot accumulate in internal envir-
onment. The final degradation product glucosamine was
able to be absorbed by the organism [21-23]; 2. Property
to control or prolong drug’s release: the viscous prop-
erty and expansibility of chitosan enabled it to retard
the release of PNS [24]; 3. Increasing permeation of
drug through intercellular space: chitosan was able to
open the cell junction and to influence the mucous
membrane reversibly [25]; 4.Improving drug’s stability in
gastrointestinal tract: PNS was surrounded by chitosan
and thus was protected against damage in acid environ-
ment of gastrointestinal tract [26]. According to some
         
Figure 4 Typical LC/MS/MS chromatograms of blank plasma of beagle dog under our detecting conditions.
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[27-29], 90% Rg1 and 80% Rb1 were degraded after 2
hours incubation in simulated gastric fluid [30]. The
amino group of chitosan could interact with acidic com-
ponents and then neutralized excessive gastric acid,
thereby reducing the damaging effect PNS encountered
in stomach and enhancing its bioavailability.
Conclusions
In this study we used chitosan as a bio-adhesive material
to prepare a modified formulation in order to improve
the bioavailability of PNS after oral administration, the
experimental result has revealed that our bio-adhesive
tablet has significantly enhanced the bioavailability of
PNS in beagle dogs, which indicates that this kind of
formulation is helpful to improve the therapeutic effect
of PNS and conducive to expand its clinical application.
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Figure 5 Mean concentration-time profiles of Notoginsenoside R1 (A), Ginsenoside Rg1 (B) and Ginsenoside Rb1 (C) in beagle dog
plasma after oral administration of two types of tablets, Normal tablet (NT) and Bio-adhesive tablet (BT). The dose of oral
administration of PNS is 90 mg/kg (n = 6).
Table 1 Pharmacokinetic parameters of Notoginsenoside
R1, Ginsenoside Rg1 and Rb1 after oral administration of
PNS normal and bio-adhesive tablets (50 mg/kg) to dogs
(n = 6)
R1 Rg1 Rb1
NT BT NT BT NT BT
Tmax(h) 2.67 5.00* 2.33 3.33* 9.33 10.67*
Cmax(ng/mL) 27.83 47.69* 55.58 42.03 1090.45 2448.90*
MRT(h) 9.93 9.19 6.40 11.54* 26.38 26.68
AUC(ng/mL)Sh 132.11 270.21* 199.08 304.06* 35579.73 53546.15*
NT: normal tablet; BT: Bio-adhesive tablet
* P < 0.05 versus oral administration of normal tablet.
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